Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq 18:00:00 29/11/2024 GMT 5-day change 1st Jan Change
92.58 USD +0.18% Intraday chart for Gilead Sciences, Inc. +2.65% +14.28%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Gilead Sciences, Inc. Announces New England Journal of Medicine Publication of PURPOSE 2 Results 11-27 CI
UBS Raises Price Target on Gilead Sciences to $96 From $70, Maintains Neutral Rating 11-22 MT
Mizuho Securities Adjusts Price Target on Gilead Sciences to $100 From $90 11-20 MT
Gilead Sciences, Inc. Presents at Jefferies London Healthcare Conference 2024, Nov-20-2024 09:30 AM 11-20
Daiwa Securities Adjusts Gilead Sciences Price Target to $90 From $73 11-18 MT
RBC Capital Adjusts Gilead Sciences Price Target to $84 From $81 11-18 MT
IDEAYA Biosciences, Inc. Appoints Stu Dorman as Chief Commercial Officer 11-18 CI
Gilead Sciences Says Most of Phase 3 Primary Biliary Cholangitis Participants Treated With Livdelzi Achieved Biochemical Response 11-15 MT
Gilead's Livdelzi Demonstrated A Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis 11-15 CI
Wolfe Research Initiates Gilead Sciences at Outperform With $110 Price Target 11-15 MT
Gilead Sciences Prices $3.5 Billion Senior Notes Offering 11-14 MT
Gilead Sciences Says Investigational HIV Prevention Drug Showed High Infection Reduction 11-13 MT
Gilead Sciences, Inc. Presents Full Purpose 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow 11-13 CI
Maxim Downgrades Gilead Sciences to Hold From Buy 11-08 MT
Truist Securities Raises Price Target on Gilead Sciences to $97 From $83, Maintains Hold Rating 11-08 MT
Raymond James Adjusts Gilead Sciences Price Target to $103 From $95, Maintains Outperform Rating 11-07 MT
JPMorgan Adjusts Price Target on Gilead Sciences to $105 From $100, Maintains Overweight Rating 11-07 MT
Barclays Adjusts Price Target on Gilead Sciences to $95 From $84, Maintains Equalweight Rating 11-07 MT
TD Cowen Adjusts Price Target on Gilead Sciences to $95 From $85, Maintains Buy Rating 11-07 MT
BMO Capital Adjusts Price Target on Gilead Sciences to $102 From $94, Maintains Outperform Rating 11-07 MT
Oppenheimer Adjusts Price Target on Gilead Sciences to $105 From $95, Maintains Outperform Rating 11-07 MT
Piper Sandler Adjusts Price Target on Gilead Sciences to $105 From $95, Maintains Overweight Rating 11-07 MT
Wells Fargo Adjusts Price Target on Gilead Sciences to $105 From $100, Maintains Overweight Rating 11-07 MT
RBC Capital Adjusts Price Target on Gilead Sciences to $81 From $75, Maintains Sector Perform Rating 11-07 MT
Goldman Sachs Adjusts Price Target on Gilead Sciences to $84 From $74, Maintains Neutral Rating 11-07 MT
Chart Gilead Sciences, Inc.
GILD: Dynamic Chart
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Employees
18,000
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
surperformance-ratings-light-chart GILEAD-SCIENCES-INCMore Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
92.58USD
Average target price
97.28USD
Spread / Average Target
+5.08%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. GILD Stock
  4. News Gilead Sciences, Inc.
  5. Argus Cuts Price Target on Gilead Sciences to $75 From $85
LAST HOURS | BLACK FRIDAY -40%: Unlock Tomorrow's Top Investments with Our Exclusive Subscriber-Only Tools!
d
:
:
BENEFIT NOW